Edition:
India

Mithra Pharmaceuticals SA (MITRA.BR)

MITRA.BR on Brussels Stock Exchange

33.40EUR
15 Aug 2018
Change (% chg)

€0.05 (+0.15%)
Prev Close
€33.35
Open
€33.50
Day's High
€33.80
Day's Low
€33.10
Volume
41,029
Avg. Vol
117,259
52-wk High
€39.35
52-wk Low
€8.90

Chart for

About

Mithra Pharmaceuticals SA is a Belgium-based company that provides pharmaceutical services. It was founded in 1999.

Overall

Beta: --
Market Cap(Mil.): €351.67
Shares Outstanding(Mil.): 34.24
Dividend: --
Yield (%): --

Financials

  MITRA.BR Industry Sector
P/E (TTM): -- 30.93 32.76
EPS (TTM): -1.10 -- --
ROI: -20.29 15.07 14.61
ROE: -32.94 16.59 16.33

BRIEF-Mithra Announces Last Subject Visit In Estelle Phase III Study In EU/Russia

* MITHRA ANNOUNCES LAST SUBJECT VISIT IN ESTELLE® PHASE III STUDY IN EU/RUSSIA AND COMPLETION OF ENDOMETRIAL SUBSTUDY

03 May 2018

BRIEF-Mithra Pharmaceuticals Announces Positive Donesta Phase IIb Study

* ANNOUNCES POSITIVE DONESTA PHASE IIB STUDY ACHIEVING PRIMARY OBJECTIVE AND CONFIRMING PROMISING SAFETY PROFILE

19 Apr 2018

BRIEF-Mithra Pharmaceuticals Signs Principle Agreement For Estelle Commercialization In Canada With Searchlight Pharma

* SIGNS PRINCIPLE AGREEMENT FOR ESTELLE COMMERCIALIZATION IN CANADA WITH SEARCHLIGHT PHARMA

12 Apr 2018

BRIEF-Mithra Pharmaceuticals Applies For Additional Estelle® Patent Based On Positive Hemostasis Data

* MITHRA APPLIES FOR ADDITIONAL ESTELLE® PATENT BASED ON POSITIVE HEMOSTASIS DATA

28 Mar 2018

BRIEF-Mithra Pharmaceuticals And Mayne Pharma's Vaginal Contraceptive Ring Accepted For Filing By FDA​

* ‍MITHRA AND MAYNE PHARMA'S VAGINAL CONTRACEPTIVE RING ACCEPTED FOR FILING BY FDA​

20 Mar 2018

BRIEF-Mithra And Alvogen Sign LSA For Vaginal Contraception Ring In Russia

* MITHRA AND ALVOGEN SIGN LSA FOR VAGINAL CONTRACEPTION RING IN RUSSIA

16 Mar 2018

BRIEF-Mithra Analysis Across A Range Of Parameters Points To Limited Hemostatic Impact For Estelle

* ANALYSIS ACROSS A RANGE OF PARAMETERS POINTS TO LIMITED HEMOSTATIC IMPACT FOR ESTELLE®,

08 Mar 2018

Earnings vs. Estimates